New hope for hard-to-treat melanoma: drug combo targets resistant tumors
NCT ID NCT05764395
First seen Apr 29, 2026 · Last updated Jun 11, 2026 · Updated 11 times
Summary
This study tests whether adding rigosertib to pembrolizumab can help people with advanced melanoma that did not respond to previous immunotherapy. Rigosertib may block cancer cell growth and make the immune system more responsive to pembrolizumab. The trial enrolled 7 adults with unresectable or metastatic melanoma. The main goal is to see how many patients' tumors shrink or stop growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.